<DOC>
	<DOCNO>NCT00976911</DOCNO>
	<brief_summary>This randomize , open-label , 2-arm study evaluate efficacy safety Avastin add chemotherapy versus chemotherapy alone patient epithelial ovarian , fallopian tube primary peritoneal cancer disease progression within 6 month platinum therapy . All patient receive standard chemotherapy either paclitaxel topotecan liposomal doxorubicin . Patients randomize Arm 2 study receive Avastin ( 10 mg/kg iv 2-weekly 15 mg/kg iv 3-weekly ) concomitantly . Anticipated time study treatment disease progression . Patients receive standard care , Arm 1 ( chemotherapy ) may opt receive Avastin ( 15 mg/kg iv 3-weekly ) . Target sample size 100-500 individual .</brief_summary>
	<brief_title>AURELIA : A Study Avastin ( Bevacizumab ) Added Chemotherapy Patients With Platinum-resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>female patient , &gt; /=18 year age epithelial ovarian , fallopian tube primary peritoneal cancer platinumresistant disease ( disease progression within &lt; 6 month platinum therapy ) EOCG performance status 02 nonepithelial tumour ovarian tumour low malignant potential previous treatment &gt; 2 chemotherapy regimen prior radiotherapy pelvis abdomen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>